1. Hand WL, Sanford JP. Mycobacterium fortuitum-a human pathogen. Ann Intern Med. 1970;73:971-977.
2.
2. American Thoracic Society. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Respir Crit Care Med. 1997;156:S1-S25.
3.
3. Weitzul S, Eichhorn PJ, Pandya AG. Nontuberculous mycobacterial infection of the skin. Dermatol Clin. 2000; 18:359-377.
4.
4. Aksu G. Mycobacterium fortuitum-chelonae complex infection in a child with complete interleukin-12 receptor beta-1 deficiency. Pediatr Infect Dis J. 2001;20:551-553.
5.
5. Fleisher TA, Bleesing JJ. Immune function. Pediatr Clin North Am. 2000;47:1197-1209.
6.
6. Wallace RJ, Swenson JM, Silcox VA, et al. Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities. J Infect Dis. 1985;152:500-514.
7.
7. Chan KH, Mann KS, Seto WH. Infection of a shunt by Mycobacteriumfortuitum: case report. Neurosurg. 1991;29:472-474.
8.
8. Dalovisio JR, Pankey GA, Wallace RJ, et al. Clinical usefulness of amikacin and doxycycline in the treatment of infection due to Mycobacterium fortuitum and Mycobacterium chelonei. Rev Infect Dis. 1981;3:1068-1074.
